Trypanocidal and leishmanicidal activity of six limonoids by Steverding, Dietmar et al.
Vol.:(0123456789) 
Journal of Natural Medicines 
https://doi.org/10.1007/s11418-020-01408-7
NOTE
Trypanocidal and leishmanicidal activity of six limonoids
Dietmar Steverding1 · Lazare S. Sidjui2,3 · Éden Ramalho Ferreira4,5 · Bathelemy Ngameni6 · Gabriel N. Folefoc3 · 
Valérie Mahiou‑Leddet7 · Evelyne Ollivier7 · G. Richard Stephenson8 · Thomas E. Storr8 · Kevin M. Tyler4
Received: 3 February 2020 / Accepted: 31 March 2020 
© The Author(s) 2020
Abstract
Six limonoids [kotschyienone A and B (1, 2), 7-deacetylgedunin (3), 7-deacetyl-7-oxogedunin (4), andirobin (5) and methyl 
angolensate (6)] were investigated for their trypanocidal and leishmanicidal activities using bloodstream forms of Trypa-
nosoma brucei and promastigotes of Leishmania major. Whereas all compounds showed anti-trypanosomal activity, only 
compounds 1–4 displayed anti-leishmanial activity. The 50% growth inhibition  (GI50) values for the trypanocidal and 
leishmanicidal activity of the compounds ranged between 2.5 and 14.9 μM. Kotschyienone A (1) was found to be the most 
active compound with a minimal inhibition concentration (MIC) value of 10 μM and  GI50 values between 2.5 and 2.9 μM. 
Only compounds 1 and 3 showed moderate cytotoxicity against HL-60 cells with MIC and  GI50 values of 100 μM and 
31.5–46.2 μM, respectively. Compound 1 was also found to show activity against intracellular amastigotes of L. major with 
a  GI50 value of 1.5 μM. The results suggest that limonoids have potential as drug candidates for the development of new 
treatments against trypanosomiasis and leishmaniasis.
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Introduction
Trypanosomiasis and leishmaniasis are devastating diseases 
for both humans and their domestic animals. Trypanosome 
parasites cause sleeping sickness in humans and nagana dis-
ease in cattle in Africa and Chagas disease in humans in 
Latin America [1, 2]. The different Leishmania parasites 
cause a variety of clinical conditions (localised skin lesions, 
mucosal ulcers, and internal organ damage) in humans 
worldwide [3]. These parasites are kinetoplastid protozoans 
and are transmitted to their mammalian host by insect vec-
tors. Treatment of these parasitoses relies on chemotherapy 
but only a few drugs are available. However, most of the 
drugs are not well tolerated or show toxic side effects, are 
not very effective, and are being increasingly subject to drug 
resistance. Therefore, effective and better-tolerated chemo-
therapies are urgently needed for the treatment of trypano-
somiasis and leishmaniasis.
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Many approved drugs are based on natural compounds 
and their derivatives [4]. In addition, a considerable num-
ber of natural products have been shown to display potent 
anti-trypanosomal and anti-leishmanial activity [5]. Plants 
that are used in traditional medicine are promising start-
ing materials for the discovery of natural compounds with 
trypanocidal and leishmanicidal activity. One such plant is 
Pseudocedrela kotschyi (Schweinf.) Harms (Meliaceae), 
which is used for the treatment of trypanosomiasis in the 
Kaduna state of Nigeria [6]. Furthermore, dichlorometh-
ane extracts of the roots of P. kotschyi have been shown 
to display anti-leishmanial activity against intracellular 
amastigotes of L. major [7].
In this study, we investigated the trypanocidal and leish-
manicidal activity of six limonoids (Fig. 1, compounds 
1–6) isolated from the roots of P. kotschyi.
Fig. 1  Structures of compounds 
1–6. Kotschyienone A (1), 
kotschyienone B (2), 7-dea-
cetylgedunin (3), 7-deacetyl-
7-oxogedunin (4), andirobin (5), 
methyl angolensate (6)
1 R = H
2 R = OH 
3 4
5 6
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Experimental
Compounds
The limonoids 1–6 were isolated from the roots of P. kotschyi 
as previously described [8]. The compounds have been char-
acterized by NMR (kotschyienone A and B (1, 2 [8], 7-dea-
cetylgedunin (3) [9, 10], 7-deacetyl-7-oxogedunin (4) [9, 11], 
andirobin (5) [12] and methyl angolensate (6) [11]) and their 
purity was judged to be about 95% by TLC. The 1H-NMR 
and 13C-NMR spectra of 1–6 are shown in Supplementary 
Figures S1–6.
Cell culture
Bloodstream forms of Trypanosoma brucei (clone 427-221a 
[13]) and human myeloid leukaemia HL-60 cells [14] were 
maintained in Baltz medium [15] supplemented with 16.7% 
heat-inactivated bovine serum in a humidified atmosphere con-
taining 5%  CO2 at 37 °C. Promastigotes of Leishmania major 
(strain MHOM/IL/81/Friedlin [16]) were cultured in Schnei-
der’s insect medium supplemented with 10% heat-inactivated 
foetal bovine serum in a humidified atmosphere containing 
5%  CO2 at 27 °C.
In vitro toxicity assay
Toxicity assays were carried out as previously described with 
some modifications [17, 18]. In brief, cells were seeded in 
96-well plates in a final volume of 200 μL of appropriate 
medium containing various concentrations of test compounds 
(tenfold dilution from 100 µM to 1 nM) and 1% DMSO. Wells 
just containing medium and 1% DMSO served as controls. 
The initial cell densities were 1 × 104/mL for T. brucei blood-
stream forms, 2.5 × 105/mL for L. major promastigotes, and 
5 × 104/mL for HL-60 cells. After 24 h incubation, 20 µL of a 
0.5 mM resazurin solution prepared in PBS was added and the 
cells were incubated for a further 48 h. Thereafter, the absorb-
ance of wells was read on a BioTek ELx808 microplate reader 
using a test wavelength of 570 nm and a reference wavelength 
of 630 nm. The 50% growth inhibition  (GI50) value, i.e., the 
concentration of a compound necessary to reduce the growth 
rate of cells by 50% compared to the control, was determined 
by linear interpolation [19]. The minimum inhibitory concen-
tration (MIC) values, i.e. the concentration of a compound 
at which all trypanosomes and human cells were killed, was 
determined microscopically.
Intra‑macrophages amastigote assay
The intra-macrophages amastigote assay was performed as 
previously described with some modification [20]. In brief, 
1 mL of J774 cells (7 × 104) suspended in RPMI supple-
mented with 10% foetal bovine serum were pipetted into 
wells of a 24 well plate containing sterile glass coverslips. 
Subsequently, cells were incubated overnight at 37 °C and 
5%  CO2 in a humidified incubator. The next day, metacy-
clic L. major promastigotes (MOI 20:1) were added and 
the plates incubated for 24 h at 34 °C and 5%  CO2 in a 
humidified incubator. After 24 h incubation, cells were 
washed 4 times with PBS to remove parasites that had not 
invaded any macrophage. Then, cells were incubated with 
compound 1 at the following concentrations: 10, 2.5, 1.25, 
0.625 and 0.1 µM. Amphotericin B (0.1 µM) was used as a 
positive control and no drug treatment as a negative control. 
After 72 h of drug incubation, cells were gently washed 4 
times with PBS and fixed with 4% paraformaldehyde for 
30 min. Thereafter, cells were washed once with water and 
stained with Giemsa for 40 min. Cells on coverslips were 
then destained using the acetone-xylene protocol as follows: 
first, pure acetone; second, pure acetone; third, acetone/
xylene 9:1; forth, acetone/xylene 7:3; fifth, acetone/xylene 
3:7; sixth, pure xylene. Finally, coverslips were mounted on 
slides with Entellan new mounting medium. Infection index 
(parasites/cell) were determined by counting approximately 
300 cells per coverslips using an Olympus BX50 microscope 
with a 100 × N.A. 1.35 oil immersion objective.
Results and discussion
All six limonoids 1–6 showed a dose-dependent inhibitory 
effect on the growth of bloodstream forms of T. brucei with 
MIC values ranging from 10 to > 100 μM and  GI50 values 
ranging from 2.48 to 14.5 μM (Table 1). Similar activities 
were also observed with promastigotes of L. major for the 
four gedunin-type limonoids 1–4 (Table 1). In contrast to 
their trypanocidal activity, the two andirobin-type limo-
noids 5 and 6 displayed no leishmanicidal activity (MIC 
and  GI50 > 100 μM, Table 1). The most active compound 
against both parasites was 1 with a MIC value of 10 μM and 
 GI50 value of 2–3 μM (Table 1). On the other hand, only 
compounds 1 and 3 showed some cytotoxic activity against 
human HL-60 cells with MIC values of 100 μM and  GI50 
values in the mid micromolar range (Table 1). The other four 
compounds (2, 4, 5 and 6) displayed no cytotoxicity against 
HL-60 cells (MIC and  GI50 > 100 μM, Table 1). Based on 
the antiparasitic and cytotoxic activities, only the gedunin-
type limonoid 1 exhibited moderated selectivity indices with 
MIC and  GI50 ratios of ≥ 10 (Table 2).
Compared with suramin and amphotericin B, two drugs 
used in the treatment of sleeping sickness and cutaneous 
leishmaniasis, respectively, the six limonoids were 10–1000 
times less active (Table 1). The higher antiparasitic activity 
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of the drugs is also reflected in their greater selectivity indi-
ces of at least > 100 (Table 2).
As compound 1 was found to be the most potent leish-
manicidal limonoid, we investigated its ability to kill L. 
major amastigotes within macrophages. The compound was 
able to reduce the parasite burden of infected macrophages 
with an  ED50 (50% effective dose) of 1.51 μM (Fig. 2). 
Thus, compound 1 was almost twice as effective in affecting 
intracellular amastigotes than extracellular promastigotes 
 (GI50(promastigotes) = 2.86 μM vs  ED50(amastigotes) = 1.51 μM). At 
10 μM, compound 1 killed completely intracellular amas-
tigotes and only vacuoles containing fragments of parasites 
could be seen (Supplementary Figure S7). However, com-
pared with amphotericin B, compound 1 was less potent in 
killing amastigotes within macrophages. The licensed drug 
was able to completely destroy intracellular amastigotes at 
a concentration of 0.1 μM (Fig. 2).
The trypanocidal and leishmanicidal activity of com-
pounds 1–6 are in good agreement with previously reported 
antiprotozoal activities. For instance, the  GI50 values for 
their anti-plasmodial activity were found to be within the 
range of 1.7–19.3 μM [8]. Compounds 3 and 4 have been 
previously reported to inhibit the growth of bloodstream 
forms of T. brucei rhodesiense with  GI50 values of 3.4 μM 
[21]. Axenic grown amastigotes of L. donovani were affected 
by 3 and 4 with  GI50 values of around 1 μM [21]. These 
activities are somewhat lower than those we found for 3 and 
4 with promastigotes of L. major. The observed differences 
may be due to that axenic grown amastigotes are more sensi-
tive as they are removed from their natural environment of 
a host cell.
Structure–activity relationship analysis revealed that the 
presence of a hydroxyl group at the C-7 position reduces 
the activity of the gedunin-type limonoids. For example, 
compound 2 with a hydroxyl group at C-7 displayed 5–6 
Table 1  In vitro trypanocidal, 
leishmanicidal and cytotoxic 
activity of the limonoids 1–6 
nt not tested
Compound T. brucei L. major HL-60 cells
MIC (μM) GI50 (μM) MIC (μM) GI50 (μM) MIC (μM) GI50 (μM)
1 10 2.48 ± 0.12 10 2.86 ± 0.89 100 31.5 ± 3.7
2 100 14.2 ± 2.9 100 14.9 ± 5.9 > 100 > 100
3 100 14.5 ± 3.2 100 11.6 ± 1.6 100 46.2 ± 6.7
4 > 100 3.18 ± 0.48 > 100 7.63 ± 2.78 > 100 > 100
5 > 100 11.5 ± 6.3 > 100 > 100 > 100 > 100
6 > 100 6.04 ± 2.25 > 100 > 100 > 100 > 100
Suramin 1 0.042 ± 0.004 nt nt > 100 > 100
Amphotericin B nt nt 0.1 0.036 ± 0.001 > 100 50.7 ± 9.3
Table 2  Selectivity indices of the limonoids 1–6 
MIC ratio  MICHL-60/MICparasite, GI50 ratio  GI50,HL-60/GI50,parasite, MIC 
ratios and  GI50 ratios were calculated from MIC and  GI50 values 
shown in Table 1
nd not determined
Compound T. brucei L. major
MIC ratio GI50 ratio MIC ratio GI50 ratio
1 10 12.7 10 11.0
2 > 1 > 7.2 > 1 > 6.7
3 1 3.2 1 4.0
4 1 > 31.4 1 > 13.1
5 1 > 8.7 1 1
6 1 > 16.6 1 1
Suramin > 100 > 2381 nd nd
Amphotericin B nd nd > 1000 1408
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Fig. 2  Effect of compound 1 on intracellular L. major amastigotes. 
After infection of J774 macrophages with metacyclic promastigotes 
of L. major, cells were treated with compound 1 or amphotericin B 
(AM) or with DMSO alone (DMSO) 24 h post infection. After 72 h 
incubation, coverslips with cells were washed with PBS, fixed with 
paraformaldehyde and stained with Giemsa. Subsequently, cells were 
destained and coverslips mounted, and the infection index deter-
mined. Mean values ± SD of three independent experiments run in 
triplicate are shown
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times lower trypanocidal and leishmanicidal activity than 
compound 1 with a hydrogen atom at the position (Fig. 1 
and Table 1). Likewise, compound 4 is 1.5–4.6 times less 
active than compound 3 which has a keto functional group 
instead of a hydroxyl group at the C-7 position (Fig. 1 and 
Table 1). These findings indicate that a slight increase in 
hydrophilicity reduces the trypanocidal and leishmanicidal 
activity of the gedunin-type limonoids.
This study has shown that phytochemical investigation of 
plants utilised in traditional medicine can yield the identifi-
cation of compounds apparently responsible for the activity 
ascribed to their indigenous use. Here it was revealed that 
six limonoids isolated form the roots of P. kotschyi, a plant 
used for treating trypanosomiasis in domestic animals in 
Nigeria [6], display anti-trypanosomal activity. Kotschyien-
one A (1) was found to be not only the most active com-
pound against T. brucei but also against L. major. Whereas 
compound 1 did not fully match the  GI50 activity criteria 
for drug candidates for African trypanosomiasis [< 0.2 μg/
mL vs 1.09 μg/mL (2.48 μM)], it fulfilled the  GI50 activity 
criteria for drug candidates for leishmaniasis [< 1 μg/mL 
vs 0.66 μg/mL (1.51 μM)] [22]. The moderate selectivity 
indices of compound 1 did not correspond with selectivity 
index activity criteria for both parasite species (Trypano-
soma > 100; Leishmania > 20 [22]). However, it should be 
pointed out that in this study a cancer cell line was used for 
determining selectivity and that, compared with non-malig-
nant cells, the cytotoxicity of compound 1 may, therefore, 
be overestimated. For example, the cytotoxicity of 1 for the 
immortalised human embryonic kidney cell line HEK239T 
was previously determined to be > 200 μg/mL [8]. Based on 
this cytotoxicity, compound 1 would match the selectivity 
index activity criteria for drug candidates for both blood-
stream forms of T. brucei and intracellular amastigotes of 
L. major. In conclusion, the gedunin-type limonoids seem 
to be a promising class of compounds for further anti-tryp-
anosomal and anti-leishmanial drug development.
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